Changes in Utilization of Generic Angiotensin Receptor Blockers Following Product Recalls in the United States

JAMA. 2020 Jan 7;323(1):87-89. doi: 10.1001/jama.2019.17521.


This pharmacoepidemiology study uses claims data to characterize angiotensin receptor blocker (ARB) prescription trends to evaluate whether recalls of ARBs prompted by discovery of potentially carcinogenic impurities shifted utilization of ARBs individually and as a drug class.

MeSH terms

  • Angiotensin Receptor Antagonists / therapeutic use*
  • Drug Prescriptions / statistics & numerical data*
  • Drug Recalls*
  • Drug Utilization / statistics & numerical data*
  • Drugs, Generic / therapeutic use*
  • Humans
  • Insurance Claim Review
  • Insurance, Pharmaceutical Services
  • United States


  • Angiotensin Receptor Antagonists
  • Drugs, Generic